Drug
Squalamine clinical trials
Includes 9 studies of Squalamine lactate.
Studies by the year they started
9 studies that test it; most in 2004 (2)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 4
Genaera Corporation (4) · Ohr Pharmaceutical Inc. (1) · Elman Retina Group (1) · Jonsson Comprehensive Cancer Center (1) · Starr Muscle (1) · OHSU Knight Cancer Institute (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Angiogenesis Inhibitors source
Studies
Open first, then newest update. How each study uses squalamine is read from its arms, and is right about nine times in ten.
Testing it · 9
- Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME)WithdrawnPhase 2Starr MuscleNCT02349516Written as Squalamine Lactate Ophthalmic Solution 0.2%
- Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)CompletedPhase 2Ohr Pharmaceutical Inc.NCT01678963Written as Squalamine lactate
- Squalamine for the Treatment in Proliferative Diabetic RetinopathyCompletedPhase 2Elman Retina GroupNCT01769183Written as Squalamine Lactate ophthalmic solution 0.2%
- Squalamine Lactate Plus Carboplatin in Treating Patients With Recurrent or Refractory Stage III or Stage IV Ovarian CancerStatus unknownPhase 2Jonsson Comprehensive Cancer CenterNCT00021385Written as squalamine lactate
- Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate CancerWithdrawnPhase 2OHSU Knight Cancer InstituteNCT00244920Written as squalamine lactate
- MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With "Wet" Age-Related Macular Degeneration (AMD)TerminatedPhase 2Genaera CorporationNCT00094120Written as MSI-1256F (Squalamine Lactate)
- A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular DegenerationTerminatedPhase 3Genaera CorporationNCT00139282Written as Squalamine Lactate
- A Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular DegenerationTerminatedPhase 2Genaera CorporationNCT00333476Written as MSI-1256F (Squalamine Lactate)
- A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular DegenerationTerminatedPhase 2Genaera CorporationNCT00089830Written as MSI-1256F (Squalamine Lactate)
Codes
What other systems call squalamine · ClinicalTrials.gg INT003706
- MeSH (NLM) C079655squalamineConfirmed NLM, Wikidata
- UNII (FDA) F8PO54Z4V7SQUALAMINEConfirmed FDA, NLM, Wikidata
- Wikidata Q15427852squalamineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C143004SqualamineOne source FDA
- DrugBank DB06461One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C079655 | squalamine | Confirmed NLM, Wikidata |
| UNII (FDA) | F8PO54Z4V7 | SQUALAMINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q15427852 | squalamine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C143004 | Squalamine | One source FDA |
| DrugBank | DB06461 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.